RxDoctor Payments Data

Michael Mineo, MD

Urology · Houston, TXNPI 1801849385

Payments from drug & device makers

$61,101in general payments, 2019–2025

Across 579 payments — averaging $105.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ortho-clinical Diagnostics, Inc.$31K
  • HMU Consumables, LLC$9K
  • Procept Biorobotics Corporation$7K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$976
  • Pfizer$972
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$5,87523%
  • Travel & lodging$7063%
  • Food & beverage$14,16554%
  • Education$1891%
  • Entertainment$170%
  • Other$5,14320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ortho-clinical Diagnostics, Inc.2$31,303
HMU Consumables, LLC4$8,847
Procept Biorobotics Corporation20$7,085
Johnson & Johnson(3 entities)43$1,075
Astellas Pharma US Inc42$976
Pfizer43$972
AbbVie(2 entities)52$967
Boston Scientific13$707
Sumitomo Pharma America, Inc.52$676
Dendreon Pharmaceuticals LLC22$592
Convatec Inc.14$582
Endo Pharmaceuticals Inc.30$539
Merck24$511
Medtronic(2 entities)12$488
Ferring Pharmaceuticals Inc.18$435
Myriad Genetic Laboratories, Inc.7$434
Bayer23$429
Progenics Pharmaceuticals, Inc.16$409
Urogen Pharma, Inc.15$400
EDAP Technomed Inc3$299
Tolmar, Inc.8$216
Blue Earth Diagnostics8$193
Coloplast4$181
Urovant Sciences Inc11$152
Aytu Biopharma, Inc.4$151
Tempus AI, Inc2$148
Baxter Healthcare1$133
Neotract Inc.1$125
AstraZeneca(2 entities)7$125
Ambu Inc.4$119
Tolmar Pharmaceuticals, Inc.2$118
Endo USA, Inc.4$104
Axogen1$99
Novartis3$96
Amgen5$91
Verity Pharmaceuticals Inc.4$89
Olympus America Inc.4$81
Alnylam Pharmaceuticals Inc.4$79
Antares Pharma, Inc.4$78
180 Medical, Inc.2$77
C. R. Bard, Inc. & Subsidiaries3$77
Axonics, Inc.4$74
Hollister Incorporated3$65
Telix Pharmaceuticals3$60
ABC Home Medical Supply, Inc.2$58
Immunitybio, Inc.2$51
Healthtronics Stone Solutions, LLC1$49
Laborie Medical Technologies Corp.1$48
Accord Healthcare, Inc.2$44
Photocure Inc1$42
Myovant Sciences Inc.2$36
Sun Pharmaceutical Industries Inc.1$30
Teleflex LLC1$27
Acerus Pharmaceuticals Corporation2$27
GSK1$24
Travere Therapeutics, Inc.2$24
Sanofi1$23
Valencia Technologies Corporation1$22
AMAG Pharmaceuticals, Inc.1$22
Metuchen Pharmaceuticals1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,101 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$564,720
Medicare patients
840
Services billed
37,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide44$599,629
MyrbetriqMirabegron218$203,260
NubeqaDarolutamide16$201,910
GemtesaVibegron233$189,787
OrgovyxRelugolix29$75,956
XgevaDenosumab21$61,815
Mirabegron ErMirabegron39$30,288
JatenzoTestosterone Undecanoate15$14,402
Silodosin133$12,029
Solifenacin Succinate138$11,055
Methenamine Hippurate111$10,570
Testosterone85$9,891
Tamsulosin Hcl600$9,749
Dutasteride184$8,371
Finasteride473$7,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$976$802,889262 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$676$265,743262 claims
BayerNubeqa$429$201,91016 claims
AmgenXgeva$91$61,81521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →